Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 20;13(1):13. doi: 10.1038/s41419-021-04474-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A The RT-qPCR (SYBR Green) analysis on the levels of SOX6 mRNA in HeLa and SiHa cells that were treated with or without cisplatin (20 μM). β-Actin (ACTB) mRNA was used as the internal control. B Western blotting analysis on the protein levels of key molecules within MAPK/ERK and PI3K-Akt-mTOR signaling pathway in HeLa and SiHa cells that were treated with or without cisplatin (20 μM). α-tubulin protein was used as the internal control. C Western blotting analysis on the protein levels of SOX6, MAP4K4, PARP, Bax, Bcl-2, and p62/SQSTM1 in HeLa and CaSki cells treated with or without cisplatin (20 μM) treatment. D Flow cytometry analysis of apoptosis in two clones of HeLa-SOX6KO cells and the control HeLa cells (lenti-V2) with or without cisplatin (20 μM) treatment. E The percentage of apoptotic cells in flow cytometry analysis. F Western blotting analysis on the protein levels of PARP, caspase 9, Bax, and Bcl-2 in two clones of HeLa-SOX6KO cells and the control HeLa cells (lenti-V2) cells with or without cisplatin (20 μM) treatment. G Representative immunofluorescent staining of SOX6 (green) and MAP4K4 (red) or p62/SQSTM1 (red) in samples collected from 14 cervical cancer patients with routine cisplatin treatment. H Relative expression level of SOX6 indicated by fluorescent density. I Relative expression level of MAP4K4 indicated by fluorescent density. J Relative expression level of SOX6 indicated by fluorescent density. K Relative expression level of p62/SQSTM1 indicated by fluorescent density. Data are the mean ± SEM of three independent experiments or at least three fields scored (*P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test, two tails for A, E, one-way ANOVA and post hoc Tukey tests for H–K). IOD, integral optical density.